ArticleScience advances2026
Photoinitiator-free gelatin hydrogel microneedles for acute gouty arthritis treatment.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photo-crosslinked microneedles (MNs) are widely used in biomedical applications, but their dependence on exogenous photoinitiators continues to pose a fundamental challenge to their further advancement. Herein, we have developed a hydrogel MN system loaded with self-assembled nanoparticles (NPs). The NPs are composed of natural polyphenols and indomethacin. The MN system is rapidly dissolving and is fabricated through an initiator-free photo-crosslinking process. Systematic investigation of the gel composition, swelling behavior, and mechanical properties of lipoic acid-modified gelatin (GelLA)-based MNs demonstrated both swelling and mechanical strength could be readily tuned. Notably, the tunable mechanical feature of GelLA enabled effective penetration of the stratum corneum, facilitating efficient transdermal drug delivery. Compared with gelatin methacryloyl, GelLA-based hydrogel MNs prepared at the same concentration exhibited superior biocompatibility, while eliminating the potential cytotoxicity associated with exogenous photoinitiators. Further in vivo evaluation in an acute gouty arthritis model demonstrated that the MN system could significantly alleviate joint inflammation through rapid drug release, highlighting its potent anti-inflammatory efficacy. Overall, this initiator-free, photo-crosslinkable GelLA-based MNs system offered a safe, efficient, and user-friendly strategy for local drug delivery in the management of acute gouty arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.